SG11202107439XA - Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same - Google Patents
Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameInfo
- Publication number
- SG11202107439XA SG11202107439XA SG11202107439XA SG11202107439XA SG11202107439XA SG 11202107439X A SG11202107439X A SG 11202107439XA SG 11202107439X A SG11202107439X A SG 11202107439XA SG 11202107439X A SG11202107439X A SG 11202107439XA SG 11202107439X A SG11202107439X A SG 11202107439XA
- Authority
- SG
- Singapore
- Prior art keywords
- dioxopiperidin
- oxoisoindolin
- fluorobenzonitrile
- piperazin
- oxy
- Prior art date
Links
- YTINZZFBHWSAGL-NDEPHWFRSA-N cc-92480 Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O YTINZZFBHWSAGL-NDEPHWFRSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962790342P | 2019-01-09 | 2019-01-09 | |
PCT/US2020/012687 WO2020146463A1 (en) | 2019-01-09 | 2020-01-08 | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107439XA true SG11202107439XA (en) | 2021-08-30 |
Family
ID=69467745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107439XA SG11202107439XA (en) | 2019-01-09 | 2020-01-08 | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
Country Status (13)
Country | Link |
---|---|
US (2) | US11370777B2 (zh) |
EP (1) | EP3908582A1 (zh) |
JP (1) | JP7483722B2 (zh) |
KR (1) | KR20210125491A (zh) |
CN (3) | CN118324742A (zh) |
AU (1) | AU2020206694A1 (zh) |
BR (1) | BR112021013435A2 (zh) |
CA (1) | CA3125756A1 (zh) |
EA (1) | EA202191620A1 (zh) |
IL (1) | IL284680A (zh) |
MX (1) | MX2021008295A (zh) |
SG (1) | SG11202107439XA (zh) |
WO (1) | WO2020146463A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113597301A (zh) * | 2019-01-09 | 2021-11-02 | 细胞基因公司 | 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法 |
US20230114674A1 (en) * | 2020-01-20 | 2023-04-13 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
MX2023012911A (es) | 2021-05-27 | 2023-11-08 | Celgene Corp | Metodos de tratamiento del mieloma multiple usando terapia combinada. |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
UA115220C2 (uk) | 2010-02-11 | 2017-10-10 | Селджин Корпорейшн | Похідні арилметоксіізоіндоліну, композиція, яка їх містить, і їх застосування |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP3399981B1 (en) * | 2016-01-08 | 2023-08-02 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
US10357489B2 (en) | 2017-07-10 | 2019-07-23 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
JP7293256B2 (ja) | 2018-05-23 | 2023-06-19 | セルジーン コーポレイション | 併用のためのbcma及びcd3に対する抗増殖性化合物及び二重特異性抗体 |
BR112020023756A2 (pt) | 2018-05-23 | 2021-02-09 | Celgene Corporation | tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila |
-
2020
- 2020-01-08 JP JP2021540023A patent/JP7483722B2/ja active Active
- 2020-01-08 EP EP20703618.7A patent/EP3908582A1/en active Pending
- 2020-01-08 CA CA3125756A patent/CA3125756A1/en active Pending
- 2020-01-08 BR BR112021013435-2A patent/BR112021013435A2/pt not_active Application Discontinuation
- 2020-01-08 EA EA202191620A patent/EA202191620A1/ru unknown
- 2020-01-08 MX MX2021008295A patent/MX2021008295A/es unknown
- 2020-01-08 AU AU2020206694A patent/AU2020206694A1/en active Pending
- 2020-01-08 WO PCT/US2020/012687 patent/WO2020146463A1/en unknown
- 2020-01-08 SG SG11202107439XA patent/SG11202107439XA/en unknown
- 2020-01-08 CN CN202410399193.6A patent/CN118324742A/zh active Pending
- 2020-01-08 KR KR1020217025072A patent/KR20210125491A/ko active Search and Examination
- 2020-01-08 CN CN202210010514.XA patent/CN114394954B/zh active Active
- 2020-01-08 US US16/737,739 patent/US11370777B2/en active Active
- 2020-01-08 CN CN202080019069.2A patent/CN113597425A/zh active Pending
-
2021
- 2021-07-07 IL IL284680A patent/IL284680A/en unknown
-
2022
- 2022-05-27 US US17/827,491 patent/US20220289713A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021013435A2 (pt) | 2021-10-19 |
CN118324742A (zh) | 2024-07-12 |
JP7483722B2 (ja) | 2024-05-15 |
JP2022518175A (ja) | 2022-03-14 |
AU2020206694A1 (en) | 2021-07-29 |
CA3125756A1 (en) | 2020-07-16 |
US11370777B2 (en) | 2022-06-28 |
CN114394954A (zh) | 2022-04-26 |
US20220289713A1 (en) | 2022-09-15 |
IL284680A (en) | 2021-08-31 |
US20200216418A1 (en) | 2020-07-09 |
EA202191620A1 (ru) | 2021-11-01 |
KR20210125491A (ko) | 2021-10-18 |
CN113597425A (zh) | 2021-11-02 |
MX2021008295A (es) | 2021-10-13 |
WO2020146463A1 (en) | 2020-07-16 |
EP3908582A1 (en) | 2021-11-17 |
CN114394954B (zh) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
IL284680A (en) | Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same | |
IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
PH12019501068A1 (en) | Crystalline forms of a magl inhibitor | |
EP3644999A4 (en) | COMPOSITIONS AND METHODS OF USE OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
SA515360022B1 (ar) | أملاح وصور صلبة من المركب (s) ــ 3 ــ(4 ــ((4ــ(مورفولينو ميثيل)بنزيل)أوكسي)-1-أوكسو أيزو إندولين-2-يل)ببريدين-2 ،6-دايون، وتركيبات تشتمل عليها، وطرق استخدامها | |
IL252368B (en) | 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it | |
SG11202106598QA (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide | |
SI3057943T1 (en) | Pyrimidine FGFR4 Inhibitors | |
IL266522B1 (en) | 2-) and in the solid state of 3,3,3,1,1,1-hexafluoropropane-2-yl-4 n a medicinal preparation in water zyl)piperazine-1-carboxylate (pyrrolidine-1-yl)-4-(trifluoromethyl | |
EP3399979A4 (en) | 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE FORMULATIONS | |
EP3735243A4 (en) | ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
IL284665A (en) | Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same | |
PH12021550456A1 (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
LT4178548T (lt) | Farmacinė kompozicija, apimanti (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il) -1-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-1-il)-3-fluorbenzonitrilą, ir jos panaudojimo būdai | |
IL292258A (en) | Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them | |
PH12018502446A1 (en) | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders | |
MX2018009742A (es) | "composicion farmaceutica que contiene un derivado de imidazolina". | |
EP3833659A4 (en) | PROCESS FOR THE PREPARATION OF (S)-N-(3-((2-((4-((1-ACETYLPYRROLIDIN-3-YL)(METHYL)AMINO)PHENYL)AMINO)-5-METHOXYPYRIMIDIN-4-YL)OXY )PHENYL)ACRYLAMIDE AND FORMULATIONS THEREOF | |
PH12018500898A1 (en) | Inhibitor of the p2x7 receptor |